Log in
Enquire now
‌

US Patent 10646480 Formulations of pimavanserin

Patent 10646480 was granted and assigned to Acadia Pharmaceuticals on May, 2020 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Acadia Pharmaceuticals
Acadia Pharmaceuticals
0
Date Filed
September 16, 2019
0
Date of Patent
May 12, 2020
0
Patent Applicant
Acadia Pharmaceuticals
Acadia Pharmaceuticals
0
Patent Application Number
16571554
0
Patent Citations
‌
US Patent 10028944 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Patent Citations Received
‌
US Patent 11840515 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
0
‌
US Patent 10981870 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form
‌
US Patent 10981871 Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C
‌
US Patent 11464768 Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
‌
US Patent 10849891 Formulations of pimavanserin
‌
US Patent 10953000 Combination of pimavanserin and cytochrome P450 modulators
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10646480
0
Patent Primary Examiner
‌
Micah Paul Young
0

Find more entities like US Patent 10646480 Formulations of pimavanserin

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.